Hengrui Pharmaceutical

I. Company Profile: Chengdu Hengrui Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing enterprise jointly invested by Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Sichuan Sheng'ao Pharmaceutical Co., Ltd., with its production base located in the Western Park of Chengdu High-tech Zone. Chengdu Hengrui first passed the GMP certification of the National Medical Products Administration in 2002 and started production in March 2003. In 2003, Chengdu Hengrui obtained the "High-tech Enterprise Certification" for the first time and has been awarded the title of Excellent High-tech Enterprise multiple times. From 2004 to 2014, Chengdu Hengrui was honored as a key taxpayer and one of the top 100 industrial taxpayers in Chengdu High-tech Zone for 11 consecutive years. Among large and medium-sized industrial enterprises in Sichuan, Chengdu Hengrui was awarded the certificate of "Top 30 Best-Efficiency Sichuan Pharmaceutical Manufacturing Industry" by the Sichuan Economic Commission and Sichuan Provincial Bureau of Statistics. Chengdu Hengrui owns two famous trademarks of Sichuan Province: Ainai (爱能) and Xianfudi (仙孚迪). Chengdu Hengrui has two famous brand products of Sichuan Province: Beishun (倍顺) and Xianfudi (仙孚迪). Chengdu Hengrui owns six well-known trademarks of Chengdu: Beterli (比特力), Beilexin (倍乐信), Aineng (爱能), Xianfudi (仙孚迪), Beishun (倍顺), and Shuangneng (爽能). II. Sales Model: The company's sales model is direct sales through pharmacies, using pharmacies as a platform to drive drug sales by providing professional services to patients with hypertension, hyperglycemia, and hyperlipidemia (the "three highs"). With the advent of the Internet+ era, the company has established a distinctive WeChat public account providing a patient self-check platform, combined with direct pharmacy sales, creating a novel O2O marketing model. The so-called "O2O" refers to integrating offline business opportunities with the Internet, making the Internet a front-end for offline transactions. Numerous successful marketing cases have been generated through this approach. III. "Three Highs" Product Series: Chengdu Hengrui Pharmaceutical Co., Ltd. is a professional enterprise in the production and sales of domestic drug series for diabetes, hypertension, and hyperlipidemia. The company offers the first localized metformin hydrochloride extended-release tablets and gliclazide extended-release tablets, the first rosiglitazone tablets (an insulin sensitizer) manufactured and marketed domestically, metformin hydrochloride and glibenclamide tablets (a compound antidiabetic drug for intensified blood glucose control), simvastatin tablets for comprehensively reversing dyslipidemia, losartan potassium capsules (an antihypertensive drug protecting vital organs), and Difrarel tablets (a French imported drug for treating diabetic retinopathy), among other series of drugs for treating the "three highs." The company also has a large number of drugs under development for treating the "three highs," such as new antidiabetic drugs (e.g., DPP-4 inhibitors and SGLT-2 inhibitors), new lipid-lowering drugs (e.g., ezetimibe), and new antihypertensive drugs.